{"id":"evolocumab-ai-pen","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Influenza"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCSK9 is a protein that degrades LDL receptors on liver cells, reducing the liver's ability to remove LDL cholesterol from blood. By blocking PCSK9, evolocumab prevents this degradation, allowing more LDL receptors to remain on the cell surface and dramatically increase LDL cholesterol uptake and clearance from circulation.","oneSentence":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:56.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (primary and secondary prevention of cardiovascular disease)"},{"name":"Familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT05284747","phase":"PHASE4","title":"EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-10-26","conditions":"Cardiovascular Disease, Myocardial Infarction, Stroke","enrollment":6019},{"nctId":"NCT03403374","phase":"PHASE4","title":"Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-08-04","conditions":"Homozygous Familial Hypercholesterolemia HoFH","enrollment":30},{"nctId":"NCT03433755","phase":"PHASE3","title":"Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-05-09","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":259},{"nctId":"NCT01879319","phase":"PHASE3","title":"Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-11","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":164},{"nctId":"NCT01849497","phase":"PHASE3","title":"Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-04-18","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 145","Repatha","AMG-145"],"phase":"phase_3","status":"active","brandName":"Evolocumab AI/pen","genericName":"Evolocumab AI/pen","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular disease), Familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}